GSK presented the latest DiViNe results at the World Vaccine Congress Europe 2019
The DiViNe partners decided to share some results on another vaccine from the project, the viral protein GAS25.
Affilogic discovered Nanofitins® against such protein and the best ligands candidates were characterized and successfully conjugated to resin beads. The affinity columns were tested by GSK in comparison with their current GAS25 purification process.
Updated results presented by GSK at the World Vaccine Congress Europe 2018
The DiViNe consortium decided to share again the latest results obtained throughout the DiViNe project at the World Vaccines Congress Europe in the “Bioprocessing and Manufacturing” sessions.
Affilogic participated to the round table: “New Ways Of “Universalizing” Vaccine Production: The DiViNe Project” and GSK presented “DiViNe Project – Affinity Chromatography For Vaccines Purification” with some updates on the Nanofitins® directed against CRM197.
2017 October – Presentation World Vaccine Congress Europe
At the world vaccine congress Europe 2017, the DiViNe partners had the chance to share the latest results obtained throughout the DiViNe project in an oral communication entitled: “Innovative affinity chromatography platform for streamlined purification of vaccines at reduces costs and lower environmental footprint”.
This presentation introduces the two innovative technologies (ie: Nanofitins and Aquaporin membrane) involved in the project to support the overall goal of the DiViNe project. The organization of the Divine consortium was underlined to demonstrate the ability of the partners to develop an innovative process from lab to industrial scale thanks to complementary expertise. First stages of this development were illustrated with a case study on CRM197, carrier protein used in about 30% of commercial glycoconjugate vaccines. Capture, release and regeneration of a lab scale affinity chromatography column containing specific Nanofitin ligands has been performed and the optimization of forward osmosis on the Aquaporin membrane led to a recovery about 90% of water molecules contained in the complex process effluent of the carrier protein.
2017 August – Presentation ICOM 2017 (International Congress on Membranes and Membrane Processes)
This presentation explains why DiViNe approach and the use of forward osmosis using Aquaporin InsideTM technology can improve water recovery during downstream operations. In this study, fermentation effluents from two families of vaccines i.e. glycoconjugates and protein antigens have been concentrated by means of aquaporin-based forward osmosis membranes. Feed flow patterns, chemical rejection, water recovery and overall membrane performance during effluent concentration were investigated. We describe a first approach to determine the feasibility of this concentration technique as a potential solution for treatment of downstream effluents from vaccine production.
For further information, please contact Maria Salud CAMILLERI-RUMBAU (Aquaporin) : email@example.com
2016 October – Poster World Vaccine Congress Europe
The DiViNe partners were happy to communicate the first results of the project at the last World Vaccines Congress in Barcelona with a poster entitled “Vaccines purification by affinity chromatography with Nanofitin ligands: demonstration with glycoconjugates”.
This poster explains why the DiViNe approach and the use of affinity chromatography with custom-designed specific Nanofitins will enable to improve the current vaccines purification process by reducing the number of downstream operations and reducing product loss.
The partners are developing a flexible Nanofitin-based platform for vaccines purification and it is illustrated on the poster with the first family of vaccines i.e. the glycoconjugate vaccines. We describe discovery and identification of Nanofitins directed against the CRM197 carrier protein, as well as their conjugation to resin.
For further information, please contact Nadège PREL (Affilogic) : firstname.lastname@example.org
2016 September – Periodic reporting for period 1 / Report summary
The DiViNe project is targeting three different families of vaccines: Family 1 (TF1): Carrier proteins used for glycoconjugates vaccines, extracted from live bacteria and for which only traditional purification technologies are applied with a low yield, Family 2 (TF2): Protein antigens that are particularly hard to separate from by products such as truncated forms, thereby requesting highly specific capture and Family 3 (TF3): Fragile enveloped viruses that are not amenable to usual purification systems. Since these target families will be covered chronologically in the course of the DiViNe project, the first 18-month focused on TF1, even though some work has already started regarding TF2 and TF3.
2015 March – Press Release: €5,8 million to start a new era in vaccine purification
The DiViNe initiative, a joint European collaboration of renowned experts, convinced the European Commission. Its main concept is “positive“ vaccines purification by affinity chromatography based on 2 innovative nanotechnologies for higher yield and lower footprint.
The six participating partners from research and industry will receive more than €5.8 million in financial support from the new EU’s Horizon 2020 Framework Program.